Chronimed changes mind and sells MEDgenesis:
This article was originally published in Clinica
Chronimed, which announced in the summer that its MEDgenesis diagnostic subsidiary was to be spun off, thus prompting a tax-free shareholder dividend, has decided to sell the company instead. Medisys UK, based in Woodbridge, Suffolk, will pay $30 million in cash and $10 million in shares for the business. Chronimed will use the funds to develop its drug distribution and patient management business.